Event Name: CPhI, ICSE & P-MEC China 2016
Event Location: Shanghai New International Expo Centre
Event Date: 21-23 June, 2016
Organizer: UBM EMEA, CCCMHPIE, UBM Sinoexpo
Email Address: email@example.com
CPhI China 2016 will be staged at Shanghai New International Expo Centre on June 21-23, 2016 together with ICSE & P-MEC China 2016, presenting a pharmaceutical gala event to the industry professionals.
For over 15 years, CPhI & P-MEC China continues to extend the upstream and downstream of industry chain and now it has developed to an international top event with over 2,800 exhibitors covering the entire pharmaceutical industry chain. The event is trully a one stop trade platform gathering API, fine chemical & intermediates, excipients & formulation, CRO & CMO, biopharmaceuticals, natural extracts, dosage, pharma machinery, packaging equipment & material, laboratory equipment, environmental protection & clean technology as well as pharma logistics.
Why you should choose CPhI, ICSE & P-MEC China:
Being the world's best known pharmaceutical industry event, CPhI & P-MEC series are presented in 9 countries every year. Amongst them, CPhI & P-MEC China has become the largest one in terms of scale. The show receives over 10 thousand overseas visitors from more than 140 countries and has become a bridge between Chinese companies and international pharmaceutical industry.
- China is the largest supply of API, starting material, critical intermediates and excipients worldwide.
- China is able to produce over 4500 different types of pharmaceutical formulations in more than 60 dosage forms, and more and more API and finished products manufacturers get GMP-certified by US, EU countries and Japan, or PQ qualified by WHO.
- There have been more than 700 APIs and 200 finished products registered and sold in stringent regulatory market like USA, EU and Japan.
- China is pushing forward of the reform of pharmaceutical regulatory review and approval system and will make great efforts to eliminate the drug application backlog within 2-3 years. The new revision of drug administration law and Chinese pharmacopoeia will improve the competitive ability of Chinese pharmaceutical companies and upgrade the products quality and help Chinese companies get access into international market.
- CROs like Wuxi Apptec, ChemPartner, Asychem, and Chiral Quest are moving into CMO space to undertake large scale downstream project for commercial productions for international pharmaceutical company's supply chain.
- Providing access to the highest number of pharmaceutical machinery and equipment suppliers from China and abroad, carrying capacity to meet different manufacturing needs with the most cost-effective price.